 LONDON, UK ACCESSWIRE March 30, 2021 Kazia NASDAQ:KZIA has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US11m upfront US7m in cash, and US4m in an equity investment, up to US281m in milestone payments and royalties in the mid-teens. 